adaptimmune
report
financial
results
business
update
thursday
november
philadelphia
oxfordshire
globe
newswire
adaptimmune
therapeutics
plc
nasdaq
adap
leader
cell
therapy
treat
cancer
report
financial
results
provide
business
update
markets
open
thursday
november
following
announcement
company
host
live
teleconference
webcast
est
gmt
day
details
press
release
live
webcast
conference
call
available
investor
section
adaptimmune
corporate
website
archive
available
call
address
participate
live
conference
call
please
dial
canada
international
placing
call
please
ask
joined
adaptimmune
conference
call
provide
confirmation
code
adaptimmune
adaptimmune
biopharmaceutical
company
focused
development
novel
cancer
immunotherapy
products
people
cancer
company
unique
specific
peptide
enhanced
affinity
receptor
platform
enables
engineering
target
destroy
cancer
across
multiple
solid
tumors
statements
release
contains
statements
within
meaning
private
securities
litigation
reform
act
pslra
statements
involve
certain
risks
uncertainties
risks
uncertainties
could
cause
actual
results
differ
materially
indicated
statements
include
without
limitation
success
cost
timing
product
development
activities
clinical
trials
ability
successfully
advance
tcr
therapeutic
candidates
regulatory
commercialization
processes
description
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
statements
well
risks
relating
business
general
refer
quarterly
report
form
filed
sec
august
sec
filings
statements
contained
press
release
speak
date
statements
made
undertake
obligation
update
statements
reflect
subsequent
events
circumstances
adaptimmune
contacts
media
relations
s√©bastien
desprez
vp
communications
investor
relations
investor
relations
juli
miller
senior
director
investor
relations
